单株抗体治疗市场规模、份额、成长分析、按生产、按来源、按治疗方法、按管理、按最终用户、按地区 - 行业预测，2025-2032

2023年单株抗体治疗市场规模为1,540.5亿美元，从2024年的1,653亿美元成长到2032年的2,904.4亿美元，复合年增长率预计为7.3%。

全球单株抗体治疗市场正在强劲成长，主要是由于癌症、自体免疫疾病和心血管疾病等慢性病盛行率上升所推动。单株抗体在治疗这些疾病方面的有效性极大地鼓励了它们的采用。此外，人口老化和文明病的增加正在刺激市场扩张。技术进步正在增强生产高度特异性抗体的能力并改善治疗结果。此外，对个人化医疗和标靶治疗的日益重视正在推动对单株抗体疗法的需求，预计该市场在未来几年将持续成长。总体而言，这些趋势显示单株抗体在医疗保健领域的前景。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析

单株抗体治疗市场规模：依产量划分

• 市场概况
• In vitro
• In vivo

单株抗体治疗市场规模：依来源分类

• 市场概况
• 人类
• 人性化
• 嵌合体
• 其他的

单株抗体治疗市场规模：依治疗方法

• 市场概况
• 自体免疫疾病与发炎性疾病
• 肿瘤学
• 血液学
• 眼科
• 其他的

单株抗体治疗市场规模：依给药方式分类

• 市场概况
• 静脉
• 皮下的
• 其他的

单株抗体治疗市场规模：依最终用户划分

• 市场概况
• 医院
• 长期照护设施
• 其他的
• 单株抗体治疗市场规模
• 北美（生产供应处理管理最终用户）
  • 美国
  • 加拿大
• 欧洲（生产供应处理管理最终用户）
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区（製造供应处理管理最终用户）
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲（生产供应处理管理最终用户）
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲（生产供应处理管理最终用户）
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
• 收益与前一年同期比较（2022-2024）

主要企业简介

• Zoetis Inc.（USA）
• Merck & Co., Inc.（USA）
• Elanco Animal Health Incorporated（USA）
• Boehringer Ingelheim International GmbH（Germany）
• Ceva Sante Animale（France）
• Virbac（France）
• Vetoquinol（France）
• Bayer AG（Germany）
• Novartis AG（Switzerland）
• Eli Lilly and Company（USA）
• Sanofi（France）
• Intervet Inc.（Netherlands）
• Alltech（Ireland）
• Huvepharma（Bulgaria）
• Kemin Industries（USA）
• Novus International（USA）
• Biomin Holding GmbH（Austria）
• ADM Animal Nutrition（USA）
• Adisseo（France）
• DSM（Netherlands）

结论和建议

Monoclonal Antibody Therapy Market size was valued at USD 154.05 Billion in 2023 and is poised to grow from USD 165.3 Billion in 2024 to USD 290.44 Billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The global monoclonal antibody therapy market is witnessing robust growth, primarily driven by the rising prevalence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. The effectiveness of monoclonal antibodies in treating these illnesses is significantly boosting their adoption. Furthermore, an aging population coupled with the increase in lifestyle-related diseases is fueling market expansion. Technological advancements have enhanced the production capabilities of highly specific antibodies, thereby improving therapeutic outcomes. Additionally, the growing emphasis on personalized medicine and targeted therapies is amplifying the demand for monoclonal antibody therapies, positioning this market for sustained growth in the coming years. Overall, these trends indicate a promising future for monoclonal antibodies in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Monoclonal Antibody Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Monoclonal Antibody Therapy Market Segmental Analysis

Global Monoclonal Antibody Therapy Market is segmented by production, source, therapy, administration, end user and region. Based on production, the market is segmented into in vitro and in vivo. Based on source, the market is segmented into human, humanized, chimeric and other. Based on therapy, the market is segmented into autoimmune and inflammatory disorders, oncology, hematology, ophthalmology and others. Based on administration, the market is segmented into intravenous, subcutaneous and other. Based on end user, the market is segmented into hospitals, long term care facilities and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market is primarily driven by notable advancements in biotechnology and genetic engineering. These developments have been crucial in creating sophisticated monoclonal antibody therapies that exhibit enhanced specificity and efficacy while minimizing side effects. Innovative techniques, including genetic manipulation, enable researchers to tailor antibodies for particular targets, thereby maximizing their therapeutic effectiveness. As a result, these scientific breakthroughs have expanded the applications of monoclonal antibody therapies and significantly improved their success rates in treating various diseases. This continued evolution in biotechnology is essential for the growth and evolution of the monoclonal antibody therapy market.

Restraints in the Monoclonal Antibody Therapy Market

The Monoclonal Antibody Therapy market faces several constraints primarily related to potential side effects and safety issues associated with these treatments. Patients may experience infusion-related reactions during administration, which can lead to discomfort and anxiety. Additionally, there is a risk of immunogenicity, where the patient's immune system reacts against the therapy itself, potentially reducing its effectiveness. Off-target effects may also occur, where the antibody interacts with unintended biological targets, leading to adverse outcomes. To mitigate these concerns, it is essential to implement rigorous safety monitoring, thorough risk assessments, and transparent communication regarding potential side effects, thereby upholding patient safety and trust in these therapies.

Market Trends of the Monoclonal Antibody Therapy Market

The monoclonal antibody therapy market is witnessing a robust trend towards increasing adoption of personalized and targeted therapies. As healthcare shifts towards individualized treatment plans, monoclonal antibodies are at the forefront of this evolution, effectively treating conditions such as cancer, autoimmune disorders, and infectious diseases. The integration of companion diagnostics, genetic profiling, and biomarker identification enhances the development and prescription of these therapies, ensuring more precise treatments that optimize therapeutic efficacy and reduce adverse effects. This growing emphasis on personalized medicine is expected to drive substantial growth in the monoclonal antibody market, reflecting a transformative approach to disease management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Monoclonal Antibody Therapy Market Size by Production & CAGR (2025-2032)

• Market Overview
• In Vitro
• In Vivo

Global Monoclonal Antibody Therapy Market Size by Source & CAGR (2025-2032)

• Market Overview
• Human
• Humanized
• Chimeric
• Other

Global Monoclonal Antibody Therapy Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Autoimmune And Inflammatory Disorders
• Oncology
• Hematology
• Ophthalmology
• Others

Global Monoclonal Antibody Therapy Market Size by Administration & CAGR (2025-2032)

• Market Overview
• Intravenous
• Subcutaneous
• Other

Global Monoclonal Antibody Therapy Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Long Term Care Facilities
• Others
• Global Monoclonal Antibody Therapy Market Size & CAGR (2025-2032)
• North America (Production, Source, Therapy, Administration, End User)
  • US
  • Canada
• Europe (Production, Source, Therapy, Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Production, Source, Therapy, Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Production, Source, Therapy, Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Production, Source, Therapy, Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Zoetis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intervet Inc. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alltech (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huvepharma (Bulgaria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novus International (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomin Holding GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADM Animal Nutrition (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adisseo (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DSM (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations